DIRS.INFO The most relevant business & tech news

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Amazon's recent AI moves have been impressive, specifically its close relationship with fellow Club holding Nvidia and, most recently, its multibillion-dollar venture investment in startup Anthropic. Best Buy : We added the electronics and appliance retailer to the portfolio shortly after the Monthly Meeting concluded. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Jim Cramer, Reckitt Benckiser, Abbott, We've, Here's, Salesforce, that's, Walt Disney, Nelson Peltz, Estee Lauder, he'd, Ford, We're, we'll, Vimal Kapur, Kapur, Linde, Eli Lilly, TikTok, Meta's Ray, Morgan Stanley, Reddit, Morgan, Ted Pick, he's, it's, Stanley Black, Decker, TJ Maxx, Wells, Wynn, Spencer Platt Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Department of Justice, Abbott Laboratories, Nvidia, Broadcom, Investors, Bausch Health, Pharmaceuticals, Costco Wholesale, Costco, GTC, Coterra, DuPont De Nemours, DuPont, stoke, Peltz, Disney, Eaton Corporation, Ford, General Motors, Wall, GE Healthcare Technologies, General Electric, Apple, Google, Bloomberg, . Honeywell, Honeywell, UBS, Meta, Microsoft, Palo Alto Networks, Palo Alto, Procter & Gamble, Starbucks, Constellation Brands, Stanley, TJX, Marshalls, Wynn Resorts, Jim Cramer's Charitable, Traders, New York Stock Exchange, Getty Locations: China, Costco, U.S, East, Mexican, Growth, HomeGoods, Wells Fargo, Macao

☆ Here's our fourth-quarter earnings report card for 31 stocks in the portfolio
▼ + stars: | 2024-03-19 | by ( Zev Fima | ) www.cnbc.com time to read: +14 min

Please note, that Abbott Laboratories is not listed below as we did not own the name before the company's earnings release. Meta Platforms had one of the best earnings reports of the entire season, as sales, earnings, and cash flow trounced expectations. Despite missing earnings expectations, Coterra Energy delivered where it matters most: discretionary and free cash flow. Honeywell 's earnings results weren't great, with sales missing across the board and segment profit results coming up mixed. Given the stock's reaction, one might wonder why we don't think the earnings results from Palo Alto Networks were flat-out ugly.

Persons: we've, Eaton, Eli Lilly, Mounjaro, Bausch, Estee Lauder, Fabrizio Freda's, Linde, shouldn't, Morgan Stanley, Procter & Gamble, Stanley Black, Decker, We're, Wells Fargo, Nikesh Arora, Palo, they've, Locker, Jim Cramer's, Jim Cramer, Jim, Satya Nadella, Nadella, SeongJoon Cho Organizations: Abbott Laboratories, Wall, GE Healthcare, Meta, Microsoft, Investors, Nvidia, Wynn Resorts, Pharmaceuticals, Broadcom, Coterra Energy, Disney, Federal Deposit Insurance Corporation, Procter &, TJX, Google Services, Constellation Brands, Costco Wholesale, Costco, DuPont, Honeywell, Palo Alto Networks, Palo Alto, Management, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: U.S, Ford, China, Macao, Las Vegas, Boston, Wells Fargo underdelivered, Seoul

☆ Strong earnings results at Bausch Health once again overshadowed by legal battle
▼ + stars: | 2024-02-22 | by ( Zev Fima | ) www.cnbc.com time to read: +4 min

Bausch Health Companies reported a fourth-quarter earnings beat on Tuesday. However , the stock's upside is likely limited until the legal battle over one of its most popular drugs is resolved. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $869 million was up 5.6% versus last year and ahead of the $863 billion consensus estimate. That makes Xifaxan responsible for 38% of Bausch Health sales, excluding B+L. Breaking that down, $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb.

Persons: we've, Bausch, Salix, companywide EBITDA, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health Companies, Pharmaceuticals, Norwich Pharmaceuticals, U.S ., Appeals, Federal Circuit, Bausch Health, Management, CNBC Locations: BLCO, Bausch

☆ For a Rainbow of Color in Winter, Look to the Willow
▼ + stars: | 2024-02-21 | by ( Margaret Roach | ) www.nytimes.com time to read: 1 min

Or maybe you’d like to produce bountiful harvests of leaves and twigs to feed livestock, or simply enliven a winter landscape with fiery color? Lisa Carper and Aric Vanselous have a willow for all of those purposes, and then some. In their trove of a nursery devoted to the genus Salix, they have several hundred species and varieties from around the world. In early 2019, Ms. Carper was browsing online for plants that might work well at the couple’s former New Jersey property. “We had a little wet patch on our four acres, and it was like, ‘What can we grow there?’” she recalled.

Persons: Lisa Carper, Aric, Carper, ”, “ Locations: New Jersey

☆ Bausch Health's decent quarter can't overcome headwind of ongoing patent dispute
▼ + stars: | 2023-11-02 | by ( Zev Fima | ) www.cnbc.com time to read: +4 min

But they aren't enough to overcome the headwind of the company's ongoing patent legislation. Good numbers, but they take a back seat to the legal battle over Bausch drug Xifaxan. Management didn't provide any update on timing for when the remaining 88% of BLCO that Bausch Health owns will be sold off. Management now expects companywide EBITDA in a range of $3.01 to $3.11 billion, versus an earlier range of $3.0 to $3.15 billion. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Bausch, Xifaxan, BCH's Bausch, companywide, Jim Cramer's, Jim Cramer, Jim, Timothy Fadek Organizations: Health, Revenue, Pharmaceuticals, Norwich Pharmaceuticals, D.C, Norwich, FDA, XIFAXAN, Management didn't, Bausch Health, Management, CNBC, International Pharmaceutical, Bloomberg, Getty Images Bloomberg, Getty Locations: New York, U.S, Interphex

☆ Troubled health name bounces after strong quarter and guidance. Here's our view on the stock
▼ + stars: | 2023-08-03 | by ( Zev Fima | ) www.cnbc.com time to read: +6 min

Another possible catalyst is the monetization of BHC's Bausch + Lomb (BLCO) stake. Bausch + Lomb update On the earnings release, management highlighted a change in thinking about how to handle their stake in Bausch + Lomb. We'll be on the lookout for more information on the Bausch + Lomb situation in the coming days. Guidance BHC management raised their full-year revenue guidance for 2023 while reaffirming their adjusted EBITDA outlook. Excluding Bausch + Lomb, the team now expects full-year revenue to be in the range of $4.5 billion to $4.65 billion.

Persons: it's, Refinitiv, BHC's Bausch, Bausch, We'll, Generics, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health, Bausch Health, Management, Bausch Health Companies, BHC's, Dentistry, CNBC Locations: BHC, Bausch, East, Africa, Canada, Asia, China

☆ Here's our Monthly Meeting rapid-fire update on all 34 stocks in the Club's portfolio
▼ + stars: | 2023-05-18 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +13 min

Here's a rapid-fire update on all 34 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Ford (F): CEO Jim Farley did a fantastic job delivering in the automaker's latest quarter, and we like his decision to scale back Ford's business in China . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. Here's a rapid-fire update on all 34 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club.

☆ Bausch Health's quarter disappoints, guidance beats. But uncertainty prevails over patent litigation
▼ + stars: | 2023-05-04 | by ( Zev Fima | ) www.cnbc.com time to read: +5 min

Xifaxan sales were also up 7%. Internationally, reported Q1 sales of $247 million missed estimates but grew 1% compared to the year-ago period. Organic sales grew 5%, driven by strength in Canada and Europe. Organic sales grew 6%. Excluding Bausch + Lomb, the team reiterated their revenue guidance of $4.45 billion to $4.6 billion, as well as their adjusted EBITDA guidance of $2.3 billion to $2.4 billion.

☆ Bausch Health's stock soars on solid quarterly results, but we have concerns about the recovery
▼ + stars: | 2023-02-23 | by ( Zev Fima | ) www.cnbc.com time to read: +4 min

Bottom line The Canadian specialty pharmaceuticals company reported solid results for the fourth quarter, along with favorable forward guidance. Bausch management on Thursday did not offer additional information, other than to reiterate its confidence in the strength of the company's patents. Bausch Health previously started the separation process via an initial public offering of Bausch + Lomb in May 2022. Results at the diversified products division — which includes neurology pharmaceutical products, generics and dentistry products — were hampered by generic competition. Notably, as Bausch Health owns most of Bausch + Lomb, the latter's financials still appear on Thursday's results.

☆ 4 of our stocks are in the news. Here's the Club's take on each development
▼ + stars: | 2022-11-03 | by ( Jeff Marks | ) www.cnbc.com time to read: +11 min

Four of our Club holdings — Costco Wholesale (COST), Amazon (AMZN), Humana (HUM) and Bausch Health (BHC) — were in the news Thursday. Bausch Health The news: Bausch Health reported third-quarter results before the opening bell Thursday. Given the latter's roughly $4.73 billion market capitalization, Bausch Health's stake is worth approximately $4.2 billion. The reason behind Bausch Health trading consistently below the valuation of its BLCO stake is debt. Secured debt means that Bausch Health has put up assets as collateral, meaning in the event of default the lenders take ownership of the collateralized assets.

☆ Nu hrăniți lebedele cu pâine, le puteți dăuna. Află cu ce se poate de hrănit
▼ + stars: | 2021-03-20 | by ( ) ziuadeazi.md time to read: +4 min

Cahul s-a stabilit un adevărat cârd de lebede, locul devenind o adevărată atracție pentru Cahuleni. Multe persoane, din dorința de a ajuta păsărele sălbatice, le hrănesc cu pâine, și nu ăși dau seama că aceasta poate dăuna păsărilor. Lebedele sunt mult mai calme însă atunci când li se oferă boabe de cereale, varză, salată sau mazăre. Această mâzgă este un mediu bun de creștere pentru o ciupercă, Chrysonilia sitophila provenită tot din pâine pe care păsările o transferă cu ciocul pe pene, vârfurile aripilor în special putând căpăta culoarea roz (culoarea ciupercii). În locul pâinii (sau al chipsurilor, biscuiților, pufuleților), cei ce doresc să ajute lebedele și rațele, le pot hrăni cu semințe de grâu, orez, ovăz, struguri, mazăre verde decongelată, râme, salată sau alte legume mărunțite.

Persons: Cook, Johnson Locations: Cahul, Käßmann and, lebedelor, and, mâzgă, biscuiților

☆ Scurtmetraj realizat cu ajutorul României şi R. Moldova, selectat în cadrul unui festival internaţional de film
▼ + stars: | 2020-10-08 | by ( ) tvrmoldova.md time to read: +1 min

Filmul „Eu sunt Dorin” se regăseşte în selecţia oficială a secţiunii de scurtmetraj a festivalului internaţional de film de la Moscova. Valeriu Andriuţă s-a născut în 1967, în R. Moldova. În 2016, Valeriu s-a angajat în proiectul său de regie, o trilogie de scurtmetraje inspirate din R. Moldova, locul său natal. Debutul său în regie a fost Chers Amis în 2017, un scurtmetraj selectat pentru un număr mare de festivaluri. A doua parte a trilogiei sale a fost Salix Caprea şi a câştigat Premiul Uniunii Cineaştilor din Moldova.

Persons: Dorin, Nikita Mihalkov, Valeriu Andriuţă, Valeriu, Gopo Locations: Moscova, Basarabia, Moldova, România, Chişinău

Search resuls for: "Salix"

12 mentions found